Defence Therapeutics Inc. DTCFF
Set alert
0.22 USD -0.01 -2.44%
As of Nov 3, 10:02 AM ET
0.2101 Day range 0.2156
0.2101 52-week range 0.7787
- YTD
- -61.33%
- 1 year
- -62.47%
- Open
- 0.2101
- Prev close
- 0.221
- Mkt cap
- 16.41M
- Vol
- 2.60K
- Avg vol
- 10.31K
- EPS
- -0.08
- P/E
- 0.00
More statistics
- Low
- 0.2101
- High
- 0.2156
YTD chart
Signals (27)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 2026 | 1 day ago |
| MACD: Buy Signal | Oct 22, 2026 | 1 week ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 8, 2026 | 1 month ago |
| RSI: Overbought | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 31, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 22, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 10, 2026 | 3 months ago |
| SMA: Bearish | Jun 15, 2026 | 4 months ago |
| SMA: Bullish | Jun 12, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 9, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 5 months ago |
| SMA: Bullish | May 29, 2026 | 5 months ago |
| MACD: Buy Signal | May 28, 2026 | 5 months ago |
| MACD: Sell Signal | May 11, 2026 | 5 months ago |
| MACD: Buy Signal | May 7, 2026 | 6 months ago |
| MACD: Sell Signal | May 6, 2026 | 6 months ago |
| SMA: Bearish | May 4, 2026 | 6 months ago |
| SMA: Bullish | Apr 30, 2026 | 6 months ago |
Newest 20 of 27.
News
- Defence Therapeutics Announces Convertible Debenture Interest Payment
- Defence Therapeutics Wins Best Poster Award and Takes Center Stage at World ADC San Diego 2026, a Key Recognition in the Field Highlighting the Potential of Its Accum Platform
- Defence Therapeutics Inc. (OTCMKTS:DTCFF) Stock Short Interest Report for September
- Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates
- Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
- Defence Therapeutics Provides Corporate Update as Company Executes on Strategic Priorities
- Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders
- Defence Therapeutics Provides Updates on Sharing Agreement
- Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs
- Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs
Your note
Sign in to keep a note on DTCFF — it syncs with the Stock Master app.